On February 3rd 2021, investors witnessed the most significant transaction in the Cannabis space since the Canopy Growth and Constellation partnership with Jazz Pharmaceuticals acquiring GW Pharmaceuticals. A UK-based cannabis company, primarily known as the business behind the FDA-approved Epidiolex. The purchase price came in at $7.2B, a whopping 50% premium as Ireland based Jazz Pharmaceuticals has just an $8.5B market cap itself. Therefore it's safe to say that Jazz Pharma is 'all in' on GW Pharma.
Big Bad Pharma & The Future of Cannabinoids
Big Bad Pharma & The Future of Cannabinoids
Big Bad Pharma & The Future of Cannabinoids
On February 3rd 2021, investors witnessed the most significant transaction in the Cannabis space since the Canopy Growth and Constellation partnership with Jazz Pharmaceuticals acquiring GW Pharmaceuticals. A UK-based cannabis company, primarily known as the business behind the FDA-approved Epidiolex. The purchase price came in at $7.2B, a whopping 50% premium as Ireland based Jazz Pharmaceuticals has just an $8.5B market cap itself. Therefore it's safe to say that Jazz Pharma is 'all in' on GW Pharma.